Advaxis, Inc. Blog | Talkmarkets | Page 1
No data available
No data available
Latest Posts
1 to 10 of 10 Posts
Biotech Stock Advaxis: Outperformer In The Making
Article By: Taki Tsaklanos Thursday, October 6, 2016 4:00 AM EDT
One of the very promising biotech companies which we covered in May of this year is Advaxis. It is a small cap with a $467M market cap with a potential solution to weaken cancer.
In this article: ADXS
Read
3 Health Stocks To Watch As Health Sector About To Break Out
Article By: Taki Tsaklanos Wednesday, May 25, 2016 10:00 PM EDT
The health sector was by far the most constructive segment up until last summer. However, it strongly broke down in August, and had a hard time recovering. We have selected 3 stocks in the health sector which deserve the attention of investors.
In this article: HZNP, XLV, ADXS
Read
E Aduro Biotech Fails Phase 2 Pancreatic Cancer; Shares Fall 16%
Article By: Terry Chrisomalis Monday, May 16, 2016 7:16 PM EDT
Phase 2b study fails to echo phase 2a results; survival improvement is statistically insignificant. Could this also be bad news for Advaxis?
In this article: ADRO, ADXS Also: BMY
Read
Money Monday With Strong Trades
Article By: Swing Trade Warrior Monday, March 21, 2016 4:38 PM EDT
I noted that KTOV had an especially interesting setup being a recent IPO and just below all time highs.
In this article: RMTI, ADXS, KTOV
Read
E Advaxis Announces That Its HPV Program Has Been Placed On FDA Clinical Hold
Article By: Terry Chrisomalis Tuesday, October 6, 2015 7:37 PM EDT
Shares of Advaxis are down 27% in after-hours trade after the company announced that the FDA has placed its HPV program on clinical hold due to one patient death.
In this article: ADXS
Read
Advaxis, Inc. Surges 9% On Collaboration With Incyte Corporation
Article By: BioMedReports Wednesday, February 11, 2015 4:46 PM EDT
Shares of Advaxis, Inc. jumped 9% to $7.70 after the company entered into a clinical trial collaboration with Incyte Corporation.
In this article: ADXS, INCY
Read
Depomed To Acquire U.S. Rights To NUCYNTA®, NUCYNTA® ER; Amgen Presents First-Line Use Of Vectibix®
Article By: BioMedReports Friday, January 16, 2015 3:44 AM EDT
Depomed Inc. announced it has entered into a definitive agreement to acquire the U.S. rights to the NUCYNTA franchise from Janssen Pharmaceuticals, Inc. for $1.05 billion.
In this article: DEPO, AMGN, DDD, ADXS, ALDX, AMBS, AMED, BSDM, BMRN, CBMG, DVCR, GALE, GB, HTBX, HEB, ISRG, OMED, PMCB, PRGB, RGDX, TGTX, WCUI
Read
Morning Call For December 22, 2014
Article By: Jim Van Meerten Monday, December 22, 2014 8:15 AM EDT
March E-mini S&Ps (ESH15 +0.23%) this morning are up +0.28% and European stocks are up +0.84% as energy producers rose after the price of crude oil stabilized.
In this article: BBRY (NOW BB), STX, TWX, FINL, GILD, ARMK, HDP, RTN, ODC, ADXS
Read
ChemoCentryx's Lead Drug Meets Phase II Objective; Novartis Reports Results Of Trial Evaluating Use Of Afinitor
Article By: BioMedReports Friday, December 12, 2014 3:13 PM EDT
Below is a look at some of the headlines for companies that made news in the healthcare sector on December 12, 2014.
In this article: NVS, CCXI, ADXS
Read
Active Stocks: ADXS, DXCM, CYTK, VRX, NLNK
Article By: BioMedReports Monday, October 20, 2014 5:03 PM EDT
U.S. stocks moved mostly higher Monday following a turbulent week.
In this article: VRX, CYTK, DXCM, NLNK, ADXS
Read
1 to 10 of 10 Posts